Matt Segar

Cardiac EP Fellow at Texas Heart Institute. Founder of ReCODE Medical (@ReCODEMedical). Using AI to Drive Clinical Innovation

[Matt Segar @MattSegar]

Medicine lost one of its greats this week. My grandpa, Dr. William (Bill) Segar, had an illustrious career that spanned nearly 60 years from @IUMedSchool and @RileyChildrens, @YaleMed, @MayoClinicCV, and @uwsmph and @WiscPediatrics.

[Matt Segar @MattSegar]

@gbiondizoccai @ccijournal @RetractionWatch It’s really not that hard to run the draft through something like ManuscriptMind and see the hallucinations

[Matt Segar @MattSegar]

@CharlesTe @drjohnm I’ve wondered this, but there seems to be a high percentage of people who discontinue dabigatran d/t GI side effects. And the GI bleed risk seems to be higher.

What do you tell patients? The cost is obviously a huge advantage.

[Matt Segar @MattSegar]

@ahmederaky @SUO_YUO I built something similar, but always had trouble figuring out how to migrate data when a user gets a new phone.
How did you end up accomplishing this?
Nice job!

[Matt Segar @MattSegar]

Been an exciting journey! Even more excited for what’s next.

[ReCODE Medical @ReCODEMedical]

We’ve been acquired!

[ReCODE Medical @ReCODEMedical]

We’ve been acquired!

[AccurKardia @AccurKardia]

Can standard ECGs flag aortic stenosis years earlier and predict higher mortality post-TAVR? Yes. 🫀

@CardioCareToday highlighted groundbreaking research by Dr. @MattSegar (@Texas_Heart). At AccurKardia, our investigational AK-AVS pipeline is turning the standard ECG into a powerful, predictive biomarker for structural heart disease.

Check the interview: https://t.co/c8jir8Iwsv

#AorticStenosis #TAVR #HealthTech #Cardiology #MedTech #AI #BetterOutcomes

[Matt Segar @MattSegar]

@alexandra_regia @DrRoderickTung @HRSonline This is such a good topic. Congrats!

[EP Lab Digest @EPLabDigest]

#WAFIB2026 ⁦@westernAFib⁩ ⁦@nmarrouche⁩ ⁦@SanaAlkhatib9⁩ ⁦@PassmanRod⁩ ⁦@Phiso_de⁩ ⁦@TinaBaykaner⁩ ⁦@MattSegar⁩

[HeartRhythm @hrs_journal]

On the standards of reporting of P-wave abnormalities in electrocardiographic studies

https://t.co/tZxm1a7NMT

[HeartRhythm @hrs_journal]

Electrocardiographic P-wave Parameters and Lifetime Atrial Fibrillation Risk: A Multi-Cohort Study

@MattSegar

https://t.co/1CiTY3Svrs

[AccurKardia @AccurKardia]

New peer-reviewed evidence for AI-ECG in aortic stenosis. Big thanks to Dr. @MattSegar and the Texas Heart Institute team for leading this work.

https://t.co/9X1w5x1epf

AK-AVS is investigational and not FDA-cleared.

[Matt Segar @MattSegar]

@balrik @ImperialEP Seems similar to this

https://t.co/oiRSyIraUg

[Matt Segar @MattSegar]

@jamespotter Great product. Is battery life optimization on the roadmap? Seems to use more battery life than I anticipated.

[HeartRhythm @hrs_journal]

Development and Validation of a Novel Machine Learning-Based Algorithm to Predict Incident Atrial Fibrillation – A Multicohort Analysis

https://t.co/BZq4eREego

[Matt Segar @MattSegar]

@shaan_khurshid @MGHHeartHealth @MGBResearchNews @broadinstitute @broad_ml4h Did you look at decision curves by chance?

[C. Michael Gibson MD @CMichaelGibson]

POLY-HF trial: Polypill containing metoprolol, spironolactone, and empagliflozin improved EF, QoL, and adherence, and reduced HF hospitalizations at 6 months in HFrEF patients compared to usual care. #AHA25 View the slides here: https://t.co/98PJIQpLRQ

[Indiana Football @IndianaFootball]

Never doubted ourselves.

[Matt Segar @MattSegar]

@SpineNeuro @SenBillCassidy I don’t think it’s a controversial take at all

[Matt Segar @MattSegar]

@DrBasedMD @olsonplanner Exactly

[Matt Segar @MattSegar]

@thisisalimirza @DrDiGiorgio Things like https://t.co/d4WGDfuFIj can help